These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19433556)

  • 1. Detection and quantification of minor human immunodeficiency virus type 1 variants harboring K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR.
    Hauser A; Mugenyi K; Kabasinguzi R; Bluethgen K; Kuecherer C; Harms G; Kunz A
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2965-73. PubMed ID: 19433556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda.
    Troyer RM; Lalonde MS; Fraundorf E; Demers KR; Kyeyune F; Mugyenyi P; Syed A; Whalen CC; Bajunirwe F; Arts EJ
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):235-50. PubMed ID: 18284323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of LigAmp and an ASPCR assay for detection and quantification of K103N-containing HIV variants.
    Church JD; Towler WI; Hoover DR; Hudelson SE; Kumwenda N; Taha TE; Eshleman JR; Eshleman SH
    AIDS Res Hum Retroviruses; 2008 Apr; 24(4):595-605. PubMed ID: 18370589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies.
    Lalonde MS; Troyer RM; Syed AR; Bulime S; Demers K; Bajunirwe F; Arts EJ
    J Clin Microbiol; 2007 Aug; 45(8):2604-15. PubMed ID: 17567789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D.
    Flys TS; Chen S; Jones DC; Hoover DR; Church JD; Fiscus SA; Mwatha A; Guay LA; Mmiro F; Musoke P; Kumwenda N; Taha TE; Jackson JB; Eshleman SH
    J Acquir Immune Defic Syndr; 2006 Aug; 42(5):610-3. PubMed ID: 16773030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine.
    Jones D; Parkin N; Hudelson SE; Guay LA; Musoke P; Mmiro F; Jackson JB; Eshleman SH
    AIDS Res Hum Retroviruses; 2005 Apr; 21(4):319-24. PubMed ID: 15943576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission.
    Flys TS; Donnell D; Mwatha A; Nakabiito C; Musoke P; Mmiro F; Jackson JB; Guay LA; Eshleman SH
    J Infect Dis; 2007 Mar; 195(5):711-5. PubMed ID: 17262714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 454 Ultra-Deep Sequencing and Allele-Specific Real-Time PCR with Regard to the Detection of Emerging Drug-Resistant Minor HIV-1 Variants after Antiretroviral Prophylaxis for Vertical Transmission.
    Hauser A; Kuecherer C; Kunz A; Dabrowski PW; Radonić A; Nitsche A; Theuring S; Bannert N; Sewangi J; Mbezi P; Dugange F; Harms G; Meixenberger K
    PLoS One; 2015; 10(10):e0140809. PubMed ID: 26469189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxis.
    Hauser A; Mugenyi K; Kabasinguzi R; Kuecherer C; Harms G; Kunz A
    PLoS One; 2011; 6(5):e20357. PubMed ID: 21655245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated.
    Johnson JA; Li JF; Morris L; Martinson N; Gray G; McIntyre J; Heneine W
    J Infect Dis; 2005 Jul; 192(1):16-23. PubMed ID: 15942889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.
    Geretti AM; Fox ZV; Booth CL; Smith CJ; Phillips AN; Johnson M; Li JF; Heneine W; Johnson JA
    J Acquir Immune Defic Syndr; 2009 Dec; 52(5):569-73. PubMed ID: 19779307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine.
    Lecossier D; Shulman NS; Morand-Joubert L; Shafer RW; Joly V; Zolopa AR; Clavel F; Hance AJ
    J Acquir Immune Defic Syndr; 2005 Jan; 38(1):37-42. PubMed ID: 15608522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012.
    Eshleman SH; Guay LA; Mwatha A; Cunningham SP; Brown ER; Musoke P; Mmiro F; Jackson JB
    AIDS Res Hum Retroviruses; 2004 Jun; 20(6):595-9. PubMed ID: 15242535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission.
    Loubser S; Balfe P; Sherman G; Hammer S; Kuhn L; Morris L
    AIDS; 2006 Apr; 20(7):995-1002. PubMed ID: 16603851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance characteristics of Allele-Specific PCR (ASPCR) in detecting drug resistance mutations among non-B HIV-1 Variants.
    Adawaye C; Fokam J; Kamangu EN; Ngwese DTA; Susin F; Moussa AM; Hig-Zounet B; Mad-Toingué J; Tidjani A; Vaira D; Moutschen M
    J Virol Methods; 2024 Jan; 323():114856. PubMed ID: 38000668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in allele-specific PCR assay with the use of polymorphism-specific primers for the analysis of minor variant drug resistance in HIV-1 subtype C.
    Rowley CF; Boutwell CL; Lockman S; Essex M
    J Virol Methods; 2008 Apr; 149(1):69-75. PubMed ID: 18295909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance.
    Rowley CF; Boutwell CL; Lee EJ; MacLeod IJ; Ribaudo HJ; Essex M; Lockman S
    AIDS Res Hum Retroviruses; 2010 Mar; 26(3):293-300. PubMed ID: 20334564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012.
    Eshleman SH; Guay LA; Wang J; Mwatha A; Brown ER; Musoke P; Mmiro F; Jackson JB
    J Acquir Immune Defic Syndr; 2005 Sep; 40(1):24-9. PubMed ID: 16123677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.
    Coovadia A; Hunt G; Abrams EJ; Sherman G; Meyers T; Barry G; Malan E; Marais B; Stehlau R; Ledwaba J; Hammer SM; Morris L; Kuhn L
    Clin Infect Dis; 2009 Feb; 48(4):462-72. PubMed ID: 19133804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and D.
    Church JD; Hudelson SE; Guay LA; Chen S; Hoover DR; Parkin N; Fiscus SA; Mmiro F; Musoke P; Kumwenda N; Jackson JB; Taha TE; Eshleman SH
    AIDS Res Hum Retroviruses; 2007 Jun; 23(6):764-8. PubMed ID: 17604538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.